Medical writing support was funded by Merck Sharp &amp

Supplementary Material PharmacoEconomics – Open

Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial Yoav Golan, Yuexin Tang, Shahrul Mt-Isa, Hong Wan, Valerie Teal, Cyrus Badshah, Sanjeet Dadwal Correspondence: Sanjeet Dadwal, Division of Infectious Diseases, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010, USA; Email: sdadwal@coh.org

Declarations

Funding This work was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,

Kenilworth, NJ, USA. Medical writing support was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Fees for Open Access were funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Conflict of Interest YT, SM-I, HW, VT, and CB are current or former employees of Merck Sharp & Dohme

Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD), and may own stock and/or stock options in Merck & Co., Inc., Kenilworth, NJ, USA. YG is an advisor and speaker for Allergan, MSD, Nabriva, Paratek, and Pfizer, a speaker for Sanofi, and an advisor to Shionogi. SD is an advisor, consultant, and speaker for MSD, an advisory board member for Janssen, and an investigator for Ansun Biopharma, Chimerix, MSD, and

Shire/Takeda.

1

Online Resource 1 Unstandardized rates of CMV-associated re-hospitalization through week 48 post-HSCT

CI confidence interval, CMV cytomegalovirus, HSCT hematopoietic stem cell transplant 95% CIs displayed on graph

2

Online Resource 2 Standardized rates of all-cause re-hospitalization through week 48 post-HSCT, per 100 participant-months: sensitivity analysis accounting for number of re-hospitalizations

CI confidence interval, HSCT hematopoietic stem cell transplant

95% CIs displayed on graph

aRates per 100 participant-months, accounting for early discontinuation or death, and accounting for number of re-hospitalizations (sensitivity analysis)

3